In vivo imaging of microglial activation with [11C](R)‐PK11195 PET in progressive supranuclear palsy
Identifieur interne : 002B66 ( Istex/Curation ); précédent : 002B65; suivant : 002B67In vivo imaging of microglial activation with [11C](R)‐PK11195 PET in progressive supranuclear palsy
Auteurs : Alexander Gerhard [Royaume-Uni] ; Iris Trender-Gerhard [Royaume-Uni] ; Federico Turkheimer [Royaume-Uni] ; Niall P. Quinn [Royaume-Uni] ; Kailash P. Bhatia [Royaume-Uni] ; David J. Brooks [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-01.
English descriptors
Abstract
Progressive supranuclear palsy (PSP) is a neurodegenerative disease presenting with voluntary gaze difficulties, early falls, and Parkinsonism. Neuronal loss, associated with intracellular neurofibrillary tangles and activated microglia, is found targeting the basal ganglia, brainstem nuclei, and frontal cortex. [11C](R)‐PK11195 PET is a marker of peripheral benzodiazepine binding sites (PBBS) expressed by activated microglia. We have used [11C](R)‐PK11195 PET to demonstrate in vivo the degree and distribution of the glial response to the degenerative process in four patients with PSP. Compared to normal age‐matched controls, the PSP patient group showed significantly increased mean [11C](R)‐PK11195 binding in the basal ganglia, midbrain, the frontal lobe, and the cerebellum. Two of the patients were rescanned after 6 to 10 months and during that time the level of microglial activation remained stable. [11C](R)‐PK11195 PET reveals a pattern of increased microglial activation in PSP patients involving cortical and subcortical regions that corresponds well with the known distribution of neuropathological changes. [11C](R)‐PK11195 PET, therefore, may help in characterizing in vivo the underlying disease activity in PSP. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20668
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002B66
Links to Exploration step
ISTEX:E14D0B5AA49F9AF524160B710910B34A5E119563Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">In vivo imaging of microglial activation with [11C](R)‐PK11195 PET in progressive supranuclear palsy</title><author><name sortKey="Gerhard, Alexander" sort="Gerhard, Alexander" uniqKey="Gerhard A" first="Alexander" last="Gerhard">Alexander Gerhard</name><affiliation wicri:level="1"><mods:affiliation>MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, London</wicri:regionArea></affiliation></author><author><name sortKey="Trender Erhard, Iris" sort="Trender Erhard, Iris" uniqKey="Trender Erhard I" first="Iris" last="Trender-Gerhard">Iris Trender-Gerhard</name><affiliation wicri:level="1"><mods:affiliation>MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, London</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>National Hospital for Neurology and Neurosurgery and Sobell Department of Motor Neuroscience and Movement Disorders, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Hospital for Neurology and Neurosurgery and Sobell Department of Motor Neuroscience and Movement Disorders, London</wicri:regionArea></affiliation></author><author><name sortKey="Turkheimer, Federico" sort="Turkheimer, Federico" uniqKey="Turkheimer F" first="Federico" last="Turkheimer">Federico Turkheimer</name><affiliation wicri:level="1"><mods:affiliation>MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, London</wicri:regionArea></affiliation></author><author><name sortKey="Quinn, Niall P" sort="Quinn, Niall P" uniqKey="Quinn N" first="Niall P." last="Quinn">Niall P. Quinn</name><affiliation wicri:level="1"><mods:affiliation>National Hospital for Neurology and Neurosurgery and Sobell Department of Motor Neuroscience and Movement Disorders, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Hospital for Neurology and Neurosurgery and Sobell Department of Motor Neuroscience and Movement Disorders, London</wicri:regionArea></affiliation></author><author><name sortKey="Bhatia, Kailash P" sort="Bhatia, Kailash P" uniqKey="Bhatia K" first="Kailash P." last="Bhatia">Kailash P. Bhatia</name><affiliation wicri:level="1"><mods:affiliation>National Hospital for Neurology and Neurosurgery and Sobell Department of Motor Neuroscience and Movement Disorders, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Hospital for Neurology and Neurosurgery and Sobell Department of Motor Neuroscience and Movement Disorders, London</wicri:regionArea></affiliation></author><author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name><affiliation wicri:level="1"><mods:affiliation>MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, London</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E14D0B5AA49F9AF524160B710910B34A5E119563</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.20668</idno><idno type="url">https://api.istex.fr/document/E14D0B5AA49F9AF524160B710910B34A5E119563/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002B66</idno><idno type="wicri:Area/Istex/Curation">002B66</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">In vivo imaging of microglial activation with [11C](R)‐PK11195 PET in progressive supranuclear palsy</title><author><name sortKey="Gerhard, Alexander" sort="Gerhard, Alexander" uniqKey="Gerhard A" first="Alexander" last="Gerhard">Alexander Gerhard</name><affiliation wicri:level="1"><mods:affiliation>MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, London</wicri:regionArea></affiliation></author><author><name sortKey="Trender Erhard, Iris" sort="Trender Erhard, Iris" uniqKey="Trender Erhard I" first="Iris" last="Trender-Gerhard">Iris Trender-Gerhard</name><affiliation wicri:level="1"><mods:affiliation>MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, London</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>National Hospital for Neurology and Neurosurgery and Sobell Department of Motor Neuroscience and Movement Disorders, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Hospital for Neurology and Neurosurgery and Sobell Department of Motor Neuroscience and Movement Disorders, London</wicri:regionArea></affiliation></author><author><name sortKey="Turkheimer, Federico" sort="Turkheimer, Federico" uniqKey="Turkheimer F" first="Federico" last="Turkheimer">Federico Turkheimer</name><affiliation wicri:level="1"><mods:affiliation>MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, London</wicri:regionArea></affiliation></author><author><name sortKey="Quinn, Niall P" sort="Quinn, Niall P" uniqKey="Quinn N" first="Niall P." last="Quinn">Niall P. Quinn</name><affiliation wicri:level="1"><mods:affiliation>National Hospital for Neurology and Neurosurgery and Sobell Department of Motor Neuroscience and Movement Disorders, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Hospital for Neurology and Neurosurgery and Sobell Department of Motor Neuroscience and Movement Disorders, London</wicri:regionArea></affiliation></author><author><name sortKey="Bhatia, Kailash P" sort="Bhatia, Kailash P" uniqKey="Bhatia K" first="Kailash P." last="Bhatia">Kailash P. Bhatia</name><affiliation wicri:level="1"><mods:affiliation>National Hospital for Neurology and Neurosurgery and Sobell Department of Motor Neuroscience and Movement Disorders, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Hospital for Neurology and Neurosurgery and Sobell Department of Motor Neuroscience and Movement Disorders, London</wicri:regionArea></affiliation></author><author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name><affiliation wicri:level="1"><mods:affiliation>MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, London</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-01">2006-01</date><biblScope unit="vol">21</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="89">89</biblScope><biblScope unit="page" to="93">93</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">E14D0B5AA49F9AF524160B710910B34A5E119563</idno><idno type="DOI">10.1002/mds.20668</idno><idno type="ArticleID">MDS20668</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>[11C](R)‐PK11195 PET</term><term>activated microglia</term><term>progressive supranuclear palsy</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Progressive supranuclear palsy (PSP) is a neurodegenerative disease presenting with voluntary gaze difficulties, early falls, and Parkinsonism. Neuronal loss, associated with intracellular neurofibrillary tangles and activated microglia, is found targeting the basal ganglia, brainstem nuclei, and frontal cortex. [11C](R)‐PK11195 PET is a marker of peripheral benzodiazepine binding sites (PBBS) expressed by activated microglia. We have used [11C](R)‐PK11195 PET to demonstrate in vivo the degree and distribution of the glial response to the degenerative process in four patients with PSP. Compared to normal age‐matched controls, the PSP patient group showed significantly increased mean [11C](R)‐PK11195 binding in the basal ganglia, midbrain, the frontal lobe, and the cerebellum. Two of the patients were rescanned after 6 to 10 months and during that time the level of microglial activation remained stable. [11C](R)‐PK11195 PET reveals a pattern of increased microglial activation in PSP patients involving cortical and subcortical regions that corresponds well with the known distribution of neuropathological changes. [11C](R)‐PK11195 PET, therefore, may help in characterizing in vivo the underlying disease activity in PSP. © 2005 Movement Disorder Society</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B66 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 002B66 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:E14D0B5AA49F9AF524160B710910B34A5E119563
|texte= In vivo imaging of microglial activation with [11C](R)‐PK11195 PET in progressive supranuclear palsy
}}
| This area was generated with Dilib version V0.6.23. |  |